DK1487972T3 - MN / CA IX-specific monoclonal antibodies generated from MN / CA IX-poor mice, as well as methods of use. - Google Patents

MN / CA IX-specific monoclonal antibodies generated from MN / CA IX-poor mice, as well as methods of use. Download PDF

Info

Publication number
DK1487972T3
DK1487972T3 DK03713562.1T DK03713562T DK1487972T3 DK 1487972 T3 DK1487972 T3 DK 1487972T3 DK 03713562 T DK03713562 T DK 03713562T DK 1487972 T3 DK1487972 T3 DK 1487972T3
Authority
DK
Denmark
Prior art keywords
antibodies
antigen
antibody
protein
cells
Prior art date
Application number
DK03713562.1T
Other languages
Danish (da)
English (en)
Inventor
Miriam Zatovicova
Jan Zavada
Gut Marta Ortova
Jaromir Pastorek
Silvia Pastorekova
Zuzanna Zavadova
Original Assignee
Inst Virology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Virology filed Critical Inst Virology
Priority claimed from PCT/US2003/005136 external-priority patent/WO2003100029A2/en
Application granted granted Critical
Publication of DK1487972T3 publication Critical patent/DK1487972T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK03713562.1T 2002-02-21 2003-02-21 MN / CA IX-specific monoclonal antibodies generated from MN / CA IX-poor mice, as well as methods of use. DK1487972T3 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US35882402P 2002-02-21 2002-02-21
US38306802P 2002-05-23 2002-05-23
US43149902P 2002-12-05 2002-12-05
PCT/US2003/005136 WO2003100029A2 (en) 2002-02-21 2003-02-21 Mn/ca ix-specific monoclonal antibodies generated from mn/ca ix-deficient mice and methods of use

Publications (1)

Publication Number Publication Date
DK1487972T3 true DK1487972T3 (en) 2015-10-19

Family

ID=33425052

Family Applications (2)

Application Number Title Priority Date Filing Date
DK03713562.1T DK1487972T3 (en) 2002-02-21 2003-02-21 MN / CA IX-specific monoclonal antibodies generated from MN / CA IX-poor mice, as well as methods of use.
DK15180634.6T DK3031910T3 (en) 2002-02-21 2003-02-21 MN / CA IX-SPECIFIC MONOCLONAL ANTIBODIES GENERATED BY MN / CA IX-DEFICIENT MOUSE AND METHODS OF USE

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK15180634.6T DK3031910T3 (en) 2002-02-21 2003-02-21 MN / CA IX-SPECIFIC MONOCLONAL ANTIBODIES GENERATED BY MN / CA IX-DEFICIENT MOUSE AND METHODS OF USE

Country Status (8)

Country Link
US (5) US7846673B2 (https=)
EP (1) EP1487972B1 (https=)
JP (4) JP4488351B2 (https=)
AU (1) AU2003217606C1 (https=)
CA (1) CA2477163C (https=)
DK (2) DK1487972T3 (https=)
HU (3) HUE026218T2 (https=)
WO (1) WO2004005348A1 (https=)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE026218T2 (en) * 2002-02-21 2016-05-30 Inst Virology MN / CA IX-Specific Monoclonal Antibodies and Methods for MN / CA IX Deficient Mice
SI2508596T1 (sl) * 2002-02-21 2016-01-29 Institute Of Virology Slovak Academy Of Sciences Monoklonska protitelesa, specifična za MN/CA IX, proizvedena iz MN/CA IX deficientnih miši, in postopki uporabe
US20090162382A1 (en) * 2002-03-01 2009-06-25 Bernett Matthew J Optimized ca9 antibodies and methods of using the same
DE60328477D1 (de) * 2002-04-16 2009-09-03 Univ California Verfahren zur prognose von nierenzellkarzinom und behandlungsauswahl mit carboanhydrase ix
US20090239247A1 (en) * 2002-12-13 2009-09-24 Harris Adrian L MN and Hypoxia
EP1896040B1 (en) 2005-06-29 2012-08-01 Threshold Pharmaceuticals, Inc. Phosphoramidate alkylator prodrugs
CA3018520C (en) * 2006-10-10 2022-05-17 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Prostate cancer-specific alterations in erg gene expression and detection and treatment methods based on those alterations
US7820159B2 (en) * 2006-10-31 2010-10-26 Instiute of Virology of the Slovak Academy of Sciences MN/CA IX and EGFR pathway inhibition
WO2009056342A1 (en) * 2007-11-02 2009-05-07 Wilex Ag Binding epitopes for g250 antibody
ES2551731T3 (es) 2007-11-19 2015-11-23 Asahi Kasei Chemicals Corporation Procedimiento para la fabricación de isocianatos y compuestos hidroxi aromáticos
US8673267B2 (en) 2009-03-02 2014-03-18 Massachusetts Institute Of Technology Methods and products for in vivo enzyme profiling
EP2295975B1 (en) * 2009-09-10 2014-06-18 Bruker Daltonik GmbH Determining the expression status of human epidermal growth factor receptor 2 (HER2) in biological samples
JP6245990B2 (ja) 2011-03-15 2017-12-13 マサチューセッツ インスティテュート オブ テクノロジー 同位体によりコード化されたレポーターによる多重検出
CA2784047C (en) 2011-07-29 2015-08-11 Milwaukee Electric Tool Corporation Tape measure
US9080849B2 (en) 2011-07-29 2015-07-14 Milwaukee Electric Tool Corporation Tape measure
US8863399B2 (en) 2011-08-26 2014-10-21 Milwaukee Electric Tool Corporation Tape measure
EP2508890A1 (en) * 2011-10-25 2012-10-10 Roche Diagnostics GmbH CAIX based diagnosis of heart failure
EP2793882A4 (en) 2011-12-22 2015-04-29 Threshold Pharmaceuticals Inc ADMINISTRATION OF HYPOXIA-ACTIVATED PRODRUGS IN COMBINATION WITH CHK1 INHIBITORS FOR THE TREATMENT OF CANCER
US9267778B2 (en) 2012-01-19 2016-02-23 Milwaukee Electric Tool Corporation Tape measure
JP2015511226A (ja) * 2012-01-31 2015-04-16 スレッショルド ファーマシューティカルズ，インコーポレイテッド 低酸素活性化プロドラッグ療法のための予測バイオマーカー
JP2015155795A (ja) * 2012-05-21 2015-08-27 東レ株式会社 癌の検出方法
USD733597S1 (en) 2012-07-30 2015-07-07 Milwaukee Electric Tool Corporation Tape measure
MX338711B (es) 2012-10-12 2016-04-28 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de las mismas.
MX362970B (es) 2013-03-13 2019-02-28 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de las mismas.
JP6847660B2 (ja) * 2013-06-07 2021-03-24 マサチューセッツ インスティテュート オブ テクノロジー リガンドをコードする合成バイオマーカーのアフィニティベースの検出
WO2015069489A1 (en) 2013-11-06 2015-05-14 Merck Patent Gmbh Predictive biomarker for hypoxia-activated prodrug therapy
EP3193940A1 (en) 2014-09-10 2017-07-26 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
CN107148425B (zh) 2014-10-29 2021-08-03 拜斯科阿迪有限公司 对mt1-mmp特异性的双环肽配体
EP3286337A4 (en) * 2015-04-23 2018-12-12 Cedars-Sinai Medical Center Automated delineation of nuclei for three dimensional (3-d) high content screening
USD785476S1 (en) 2015-12-10 2017-05-02 Milwaukee Electric Tool Corporation Tape measure
USD785475S1 (en) 2015-12-10 2017-05-02 Milwaukee Electric Tool Corporation Tape measure
USD783430S1 (en) 2016-01-07 2017-04-11 Milwaukee Electric Tool Corporation Tape measure
USD783429S1 (en) 2016-01-07 2017-04-11 Milwaukee Electric Tool Corporation Tape measure
USD787347S1 (en) 2016-01-07 2017-05-23 Milwaukee Electric Tool Corporation Tape measure
EP3440013A4 (en) 2016-04-08 2021-03-17 Massachusetts Institute of Technology METHOD FOR SPECIFIC PROFILING OF PROTEASE ACTIVITY ON LYMPH NODES
WO2017193070A1 (en) 2016-05-05 2017-11-09 Massachusetts Institute Of Technology Methods and uses for remotely triggered protease activity measurements
USD788611S1 (en) 2016-06-01 2017-06-06 Milwaukee Electric Tool Corporation Tape measure
EP3525829A1 (en) 2016-10-11 2019-08-21 Medimmune Limited Antibody-drug conjugates with immune-mediated therapy agents
WO2018115203A1 (en) 2016-12-23 2018-06-28 Bicyclerd Limited Peptide derivatives having novel linkage structures
CA3059358A1 (en) 2017-04-07 2018-10-11 Massachusetts Institute Of Technology Methods to spatially profile protease activity in tissue and sections
US10857196B2 (en) 2017-04-27 2020-12-08 Bicycletx Limited Bicyclic peptide ligands and uses thereof
EP3645549A1 (en) 2017-06-26 2020-05-06 BicycleRD Limited Bicyclic peptide ligands with detectable moieties and uses thereof
JP7670481B2 (ja) 2017-08-04 2025-04-30 バイスクルテクス・リミテッド Ｃｄ１３７に対して特異的な二環式ペプチドリガンド
TWI825046B (zh) 2017-12-19 2023-12-11 英商拜西可泰克斯有限公司 Epha2特用之雙環胜肽配位基
GB201721265D0 (en) 2017-12-19 2018-01-31 Bicyclerd Ltd Bicyclic peptide ligands specific for EphA2
CN111902429A (zh) 2018-02-23 2020-11-06 拜斯科技术开发有限公司 多聚体双环肽配体
WO2019173332A1 (en) 2018-03-05 2019-09-12 Massachusetts Institute Of Technology Inhalable nanosensors with volatile reporters and uses thereof
CA3098103A1 (en) 2018-05-23 2019-11-28 Adc Therapeutics Sa Molecular adjuvant
US11732009B2 (en) 2018-06-08 2023-08-22 Glympse Bio, Inc. Activity sensor with tunable analyte
US11028425B2 (en) 2018-06-08 2021-06-08 Glympse Bio, Inc. Diagnosis and monitoring of liver disease
GB201810316D0 (en) 2018-06-22 2018-08-08 Bicyclerd Ltd Peptide ligands for binding to EphA2
IL279489B2 (en) 2018-06-22 2025-10-01 Bicycletx Ltd Bicyclic peptide ligands specific for nectin-4, a drug conjugate containing the peptide ligands and a pharmaceutical composition containing the drug conjugate
US12173349B2 (en) 2018-09-25 2024-12-24 Massachusetts Institute Of Technology Lung protease nanosensors and uses thereof
WO2020084305A1 (en) 2018-10-23 2020-04-30 Bicycletx Limited Bicyclic peptide ligands and uses thereof
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
WO2020128527A1 (en) 2018-12-21 2020-06-25 Bicyclerd Limited Bicyclic peptide ligands specific for pd-l1
US12492224B2 (en) 2018-12-21 2025-12-09 Bicycletx Limited Bicyclic peptide ligands specific for PD-L1
GB201900529D0 (en) 2019-01-15 2019-03-06 Bicycletx Ltd Bicyclic peptide ligands specific for CD38
US11835522B2 (en) 2019-01-17 2023-12-05 Massachusetts Institute Of Technology Sensors for detecting and imaging of cancer metastasis
US12338483B2 (en) 2019-02-28 2025-06-24 Georgia Tech Research Corporation Compositions and methods for logic-gated profiling of biologic activity
US12351645B2 (en) 2019-05-06 2025-07-08 Navi Bio-Therapeuticis, Inc. Anti-carbonic anhydrase IX antibody
TWI860386B (zh) 2019-07-30 2024-11-01 英商拜西可泰克斯有限公司 異質雙環肽複合物
CA3156540A1 (en) * 2019-11-05 2021-05-14 Miriam Zatovicova Humanized anti-ca ix antibodies and methods of their use
CN111273036B (zh) * 2020-03-06 2021-06-15 中国农业科学院兰州兽医研究所 检测口蹄疫非结构蛋白抗体的单抗竞争化学发光试剂盒
AU2021322934A1 (en) 2020-08-03 2023-03-30 Bicycletx Limited Peptide-based linkers
JP2023542867A (ja) 2020-09-11 2023-10-12 グリンプス バイオ， インコーポレイテッド 疾患の検出／診断、病期分類、モニタリング及び処置のための生体外でのプロテアーゼ活性検出
US20230372528A1 (en) 2020-10-16 2023-11-23 University Of Georgia Research Foundation, Inc. Glycoconjugates
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
EP4426727A2 (en) 2021-11-03 2024-09-11 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody
CN116167592B (zh) * 2023-04-20 2023-06-23 交通运输部天津水运工程科学研究所 一种河流溢油风险防控和决策支持系统

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5401638A (en) 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US5989838A (en) 1992-03-11 1999-11-23 Institute Of Virology, Slovak Academy Of Sciences Immunological methods of detecting MN proteins and MN polypeptides
US6027887A (en) 1992-03-11 2000-02-22 Institute Of Virology, Solvak Academy Of Sciences MN gene and protein
US5972353A (en) 1992-03-11 1999-10-26 Institute Of Virology, Slovak Academy Of Sciences MN proteins, polypeptides, fusion proteins and fusion polypeptides
US6297051B1 (en) 1997-01-24 2001-10-02 Institute Of Virology, Slovak Academy Of Sciences MN gene and protein
US6069242A (en) 1992-03-11 2000-05-30 Institute Of Virology, Slovak Academy Of Sciences MN gene and protein
US6297041B1 (en) * 1992-03-11 2001-10-02 Institute Of Virology, Slovak Academy Of Sciences MN gene and protein
US5955075A (en) 1992-03-11 1999-09-21 Institute Of Virology, Slovak Academy Of Sciences Method of inhibiting tumor growth using antibodies to MN protein
US6093548A (en) 1992-03-11 2000-07-25 Institute Of Virology, Slovak Academy Of Sciences Detection and quantitation of MN-specific antibodies.
US6774117B1 (en) 1992-03-11 2004-08-10 Institute Of Virology, Slovak Academy Of Sciences MN gene and protein
US5981711A (en) 1992-03-11 1999-11-09 Institute Of Virology, Slovak Academy Of Sciences MN-specific antibodies and hybridomas
US6204370B1 (en) 1992-03-11 2001-03-20 Institute Of Virology, Slovak Academy Of Sciences MN gene and protein
US5387676A (en) * 1992-03-11 1995-02-07 Ciba Corning Diagnostics Corp. MN gene and protein
AU2861695A (en) * 1994-06-15 1996-01-05 Ciba Corning Diagnostics Corp. Mn gene and protein
US6451977B1 (en) * 1998-02-26 2002-09-17 Genentech, Inc. Fused polypeptides
ES2296412T3 (es) 1998-10-23 2008-04-16 Institute Of Virology Gen y proteina mn.
AU2002351208A1 (en) * 2001-12-03 2003-06-17 Abgenix, Inc. Antibodies against carbonic anhydrase IX (CA IX) tumor antigen
HUE026218T2 (en) * 2002-02-21 2016-05-30 Inst Virology MN / CA IX-Specific Monoclonal Antibodies and Methods for MN / CA IX Deficient Mice
AU2003268180A1 (en) 2002-08-23 2004-03-11 Chiron Corporation Compositions and methods of therapy for cancers characterized by expression of the tumor-associated antigen mn/ca ix
WO2008103327A2 (en) 2007-02-20 2008-08-28 Bayer Pharmaceuticals Corporation Mn/ca ix and bladder cancer
WO2009056342A1 (en) * 2007-11-02 2009-05-07 Wilex Ag Binding epitopes for g250 antibody

Also Published As

Publication number Publication date
HK1226095B (en) 2017-09-22
AU2003217606B8 (en) 2003-12-12
DK3031910T3 (en) 2017-10-23
JP4514820B2 (ja) 2010-07-28
EP1487972B1 (en) 2015-08-12
US20050031623A1 (en) 2005-02-10
JP2005535601A (ja) 2005-11-24
HUE026218T2 (en) 2016-05-30
US20080176310A1 (en) 2008-07-24
AU2003217606C1 (en) 2008-07-17
US7816493B2 (en) 2010-10-19
CA2477163C (en) 2010-07-27
CA2477163A1 (en) 2003-12-04
HK1177474A1 (en) 2013-08-23
AU2003217606B2 (en) 2007-11-22
US20080176258A1 (en) 2008-07-24
US20150266971A1 (en) 2015-09-24
AU2003217606A2 (en) 2003-12-12
HUE026277T2 (en) 2016-05-30
JP5199228B2 (ja) 2013-05-15
JP2010111679A (ja) 2010-05-20
HUE036891T2 (hu) 2018-08-28
EP1487972A2 (en) 2004-12-22
US7833728B2 (en) 2010-11-16
JP2013060452A (ja) 2013-04-04
EP1487972A4 (en) 2006-05-31
JP5271443B2 (ja) 2013-08-21
JP4488351B2 (ja) 2010-06-23
US20080177046A1 (en) 2008-07-24
JP2009114198A (ja) 2009-05-28
WO2004005348A1 (en) 2004-01-15
AU2003217606A1 (en) 2003-12-12
US7846673B2 (en) 2010-12-07

Similar Documents

Publication Publication Date Title
DK1487972T3 (en) MN / CA IX-specific monoclonal antibodies generated from MN / CA IX-poor mice, as well as methods of use.
US7087727B2 (en) Periostin-based diagnostic assays
US20080176268A1 (en) MN Gene and Protein
WO2003100029A2 (en) Mn/ca ix-specific monoclonal antibodies generated from mn/ca ix-deficient mice and methods of use
EP2508596B1 (en) MN/CA IX-specific monoclonal antibodies generated from MN/CA IX-deficient mice and methods of use
AU2008200868B2 (en) Soluble form of carbonic anhydrase IX (s-CA IX), assays to detect s-CA IX, CA IX's coexpression with HER-2/neu/c-erb-B2, and CA IX-specific monoclonal antibodies to non-immunodominant epitopes
HK1226095A1 (en) Mn/ca ix-specific monoclonal antibodies generated from mn/ca ix-deficient mice and methods of use
HK1177474B (en) Mn/ca ix-specific monoclonal antibodies generated from mn/ca ix-deficient mice and methods of use
JP2002515848A (ja) Ｍｎ遺伝子およびｍｎ蛋白質